GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » IDT Australia Ltd (ASX:IDT) » Definitions » EV-to-EBITDA

IDT Australia (ASX:IDT) EV-to-EBITDA : -9.14 (As of Jun. 26, 2025)


View and export this data going back to 1991. Start your Free Trial

What is IDT Australia EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, IDT Australia's enterprise value is A$42.35 Mil. IDT Australia's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 was A$-4.63 Mil. Therefore, IDT Australia's EV-to-EBITDA for today is -9.14.

The historical rank and industry rank for IDT Australia's EV-to-EBITDA or its related term are showing as below:

ASX:IDT' s EV-to-EBITDA Range Over the Past 10 Years
Min: -85.74   Med: -3.06   Max: 128.62
Current: -9.15

During the past 13 years, the highest EV-to-EBITDA of IDT Australia was 128.62. The lowest was -85.74. And the median was -3.06.

ASX:IDT's EV-to-EBITDA is ranked worse than
100% of 731 companies
in the Drug Manufacturers industry
Industry Median: 13.72 vs ASX:IDT: -9.15

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2025-06-26), IDT Australia's stock price is A$0.091. IDT Australia's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was A$-0.013. Therefore, IDT Australia's PE Ratio (TTM) for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


IDT Australia EV-to-EBITDA Historical Data

The historical data trend for IDT Australia's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IDT Australia EV-to-EBITDA Chart

IDT Australia Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 45.26 38.89 -53.11 -1.82 -8.39

IDT Australia Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -1.82 - -8.39 -

Competitive Comparison of IDT Australia's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, IDT Australia's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IDT Australia's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, IDT Australia's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where IDT Australia's EV-to-EBITDA falls into.


;
;

IDT Australia EV-to-EBITDA Calculation

IDT Australia's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=42.345/-4.631
=-9.14

IDT Australia's current Enterprise Value is A$42.35 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. IDT Australia's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 was A$-4.63 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


IDT Australia  (ASX:IDT) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

IDT Australia's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.091/-0.013
=At Loss

IDT Australia's share price for today is A$0.091.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. IDT Australia's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was A$-0.013.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


IDT Australia EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of IDT Australia's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


IDT Australia Business Description

Traded in Other Exchanges
N/A
Address
45 Wadhurst Drive, Boronia, Melbourne, VIC, AUS, 3155
IDT Australia Ltd produces, develops, and supplies pharmaceutical products. It is engaged in the provision of research and development and other technical services for the pharmaceutical and allied industries. The company is involved in the manufacture of Active Pharmaceutical Ingredients (API) and Finished Dose Forms (FDF), microbiological and analytical testing, clinical packaging, and pharmacy services.